Radiotherapy
Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can also be supplemented with HDR brachytherapy.
Treatment decision for prostate cancer with an intermediate risk level
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Radical prostatectomy
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Surgical removal of the prostate (radical prostatectomy – RPE) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups.
Accompanies you through this topic
PD Dr. Felix Preisser
Consultant
Your questions are welcome
info(at)martini-klinik.de
+49 (0)40 7410-51300
HDR brachytherapy
Brachytherapy is a form of internal radiotherapy. It can be administered as low-dose rate (LDR) or high-dose rate (HDR) brachytherapy. HDR brachytherapy involves temporary implantation of a high-dose radiation source and can be used against moderately and highly aggressive tumours. In HDR brachytherapy, a radiation source is implanted under anaesthetic and then removed a few minutes later. This procedure is repeated one week later and is usually accompanied by percutaneous radiotherapy.
Focal treatment
In most patients with a prostate carcinoma, the entire prostate has to be treated. This is because, in over 80% of cases, numerous tumour lesions are distributed throughout the entire prostate. However, if the tumour is unifocal (limited to a single lesion) or confined to a specific area (e.g. a lateral lobe), and if your PSA level is below 15 ng/ml, it can be removed in a selective, targeted procedure without having to remove the entire prostate.
Treatment decisions when prostate cancer is detected early
Treatment decisions for high-risk prostate cancer
What treatment options are available for low-risk prostate cancer?
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Surgical removal of the prostate (prostatectomy) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups. Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can be supplemented with HDR brachytherapy. If the tumour is contained in a specific area, localised removal of the tumour lesion (focal treatment) may also be an option.